DDInter740 DDInter1652
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
Flecainide {u} (Compound) downregulates {v} (Gene) RRM2
Flecainide {u} (Compound) causes {v} (Side Effect) Shock
Flecainide (Compound) resembles Mefloquine (Compound)
Flecainide (Compound) binds CYP2D6 (Gene)
Flecainide (Compound) upregulates MTHFD2 (Gene)
Flecainide (Compound) downregulates RRM2 (Gene)
Flecainide (Compound) causes Shock (Side Effect)